Executive Summary: The 16-to-50 Employer: Enough Scale for Real Plan Design, Not Enough for Self-Funded Confidence
LFP-04.04 — The 1-to-50 Market#
At 16 to 50 employees, both level funded and fully insured can work. Neither is obviously wrong. The KFF 2025 Employer Health Benefits Survey reports that 37% of covered workers in firms with 10 to 199 employees are enrolled in level funded plans. This segment is level funded’s natural market: large enough for favorable stop loss economics and meaningful analytics, not large enough to self-fund comfortably without the stop loss protection layer.
Scale enables plan design options smaller groups cannot access. At 16 or more lives, custom benefit structures become economically justifiable as administrative cost spreads across a viable member base. Tiered benefit options become practical. Pharmacy management becomes a lever at 25 or more covered lives: step therapy, prior authorization for specialty drugs, and reference pricing produce measurable savings when pharmacy represents 20% to 30% of total spending. Wellness programs become feasible; the KFF 2025 survey reports 22% of small firms now offer biometric screenings, up 9 percentage points from 2024. HR capacity typically exists at this size for the first time, providing someone to engage with claims data and renewal documentation.
A 25-person group with $500,000 in expected annual claims and actual claims of $400,000 could see $50,000 to $100,000 in surplus return. Over multiple favorable years, compounding surplus return changes the total cost calculation substantially relative to annual fully insured renewal pricing. Claims data at this size enables plan design adjustments at renewal: identifying disproportionate ER utilization and adding telemedicine, identifying chronic condition concentration and adding disease management. These adjustments compound across plan years in ways a single-year price comparison never captures.
Fully insured remains the superior choice for specific employer profiles. Simplicity has genuine value for employers who will not engage with plan management. Community rating absorbs the cost of a member on $300,000 annual biologic therapy that level funded would laser. Large carrier member engagement infrastructure may exceed what a small TPA provides for employers who view the benefit experience as part of the employment value proposition.
The employer at this size should evaluate structural questions before leading with price. Does the employer want claims data and will they act on it? Do they have the risk tolerance for renewal volatility from an adverse claims year? Does their broker have genuine level funded expertise? Do known high-cost members exist whose laser would materially alter the economics? A 3% to 5% first-year savings does not justify added complexity for a low-engagement employer. A 12% to 15% savings likely does for an employer who will compound those savings through active plan management. The employer who buys level funded only on a single-year price comparison, without understanding the multi-year dynamics, experiences the downside without accumulating the surplus and data advantages that justify the structure.